share_log

Needham Maintains Buy on Cidara Therapeutics, Adjusts Price Target To $25

Needham Maintains Buy on Cidara Therapeutics, Adjusts Price Target To $25

Needham维持对Cidara Therapeutics的买入,将目标股价调整至25美元
Benzinga ·  04/25 14:23

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy, adjusts target to $25 from $3.

Needham分析师约瑟夫·斯金格维持Cidara Therapeutics(纳斯达克股票代码:CDTX)的买入,将目标从3美元调整至25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发